Actively Recruiting
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Led by Ottawa Heart Institute Research Corporation · Updated on 2026-03-05
150
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
Sponsors
O
Ottawa Heart Institute Research Corporation
Lead Sponsor
S
Sun Life Assurance Company of Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this vanguard trial is to test whether clients of Sun Life are willing to join in a quit smoking program that offers counselling and tobacco cessation products to all participants over a 12-month period. The study team will track the safety and usage of 3 types of cessation products as well as the effectiveness of a virtual pharmacy (i.e. cessation products delivered to participants directly from a pharmacy). The goal is to recruit a minimum of 150 participants for this Vanguard phase. The purpose of this study is to look at 3 approved smoking cessation products used in combination with counselling and virtual delivery of the smoking cessation products. The goal is to track product usage, safety, and adherence (how much of the products people use and how many counselling sessions they complete). Within the study there will also be an observational group who will not receive study medication but who will receive free virtual coaching and follow-up for smoking cessation and complete study questionnaires.
CONDITIONS
Official Title
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (≥18 years)
- Current cigarette smokers (more than 5 cigarettes per day) interested in reducing or quitting in the next 6 months
- Able to provide informed consent
- Living in Ontario, Canada
You will not qualify if you...
- Contraindications to nicotine replacement therapy, cytisine, or varenicline
- Used any study medication in the past 7 days
- Enrolled in another formal smoking cessation program
- Pregnant or breastfeeding individuals
- Unable to engage in follow-up due to acute mental illness, cognitive impairment, or language barriers
- Other conditions that may interfere with participation or study outcomes, such as being acutely unwell or having a life expectancy less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Actively Recruiting
Research Team
E
Evyanne Quirouette
CONTACT
L
Leah Margetson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here